- Home
- SLS vs VOR Comparison
SLS vs VOR Comparison
Compare SLS & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SLS | VOR |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 208.0M | 207.1M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | SLS | VOR |
|---|---|---|
| Price | $3.79 | $14.16 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 10 |
| Target Price | $7.00 | ★ $64.78 |
| AVG Volume (30 Days) | ★ 14.1M | 1.3M |
| Earning Date | 11-12-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.85 | $2.62 |
| 52 Week High | $5.18 | $65.80 |
Technical Indicators
Market Signals| Indicator | SLS | VOR |
|---|---|---|
| Relative Strength Index (RSI) | 58.28 | N/A |
| Support Level | $3.23 | N/A |
| Resistance Level | $4.42 | N/A |
| Average True Range (ATR) | 0.62 | 0.00 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 46.38 | 0.00 |
Price Performance
Historical ComparisonAbout SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
About VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.